Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalTimes Interest Earned

MoonLake Immunotherapeutics (MLTX) Return on Equity (2021 - 2026)

MoonLake Immunotherapeutics' Return on Equity history spans 6 years, with the latest figure at 0.01% for Q1 2026.

  • Quarterly Return on Equity fell 1.0% to 0.01% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.01% through Mar 2026, down 1.0% year-over-year, with the annual reading at 0.01% for FY2025, 0.0% changed from the prior year.
  • Return on Equity came in at 0.01% for Q1 2026, down from 0.01% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.06% in Q1 2022 to a low of 0.03% in Q2 2022.
  • The 5-year median for Return on Equity is 0.0% (2025), against an average of 0.0%.
  • Year-over-year, Return on Equity plummeted -35bps in 2022 and then rose 2bps in 2023.
  • MoonLake Immunotherapeutics' Return on Equity stood at 0.01% in 2022, then skyrocketed by 90bps to 0.0% in 2023, then tumbled by -193bps to 0.0% in 2024, then crashed by -202bps to 0.01% in 2025, then decreased by -20bps to 0.01% in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Return on Equity are 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025).